期刊文献+

探讨不同剂量替加环素治疗泛耐药鲍曼不动杆菌重症肺炎的效果 被引量:1

Effect of different doses of tigecycline on severe pneumonia caused by pan-resistant Acinetobacter baumannii
下载PDF
导出
摘要 目的探讨泛耐药鲍曼不动杆菌重症肺炎采用不同剂量替加环素治疗的效果。方法50例泛耐药鲍曼不动杆菌重症肺炎患者,依据替加环素剂量不同分为常规剂量组和增加剂量组,每组25例。常规剂量组患者给予常规剂量替加环素治疗,增加剂量组患者给予增加剂量替加环素治疗。比较两组患者的细菌清除情况、不良反应发生情况。结果增加剂量组患者细菌总清除率为88.0%(22/25),高于常规剂量组的64.0%(16/25),差异具有统计学意义(P<0.05)。增加剂量组患者不良反应发生率为12.0%(3/25),与常规剂量组的8.0%(2/25)比较差异无统计学意义(P>0.05)。结论泛耐药鲍曼不动杆菌重症肺炎采用增加剂量替加环素治疗的效果较常规剂量好。 Objective To discuss the effect of different doses of tigecycline on severe pneumonia caused by pan-resistant Acinetobacter baumannii.Methods A total of 50 patients with severe pneumonia caused by pan-resistant Acinetobacter baumannii were divided into conventional dose group and increased dose group according to different doses of tigecycline,with 25 cases in each group.Patients in the conventional dose group were treated with conventional dose of tigecycline,while patients in the increased dose group were treated with increased dose of tigecycline.The bacterial clearance and occurrence of adverse reactions of the two groups were compared.Results The total bacterial clearance rate of increased dose group was 88.0%(22/25),which was higher than 64.0%(16/25)of conventional dose group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of increased dose group was 12.0%(3/25),which had no statistically significant difference compared with 8.0%(2/25)of conventional dose group(P>0.05).Conclusion Increased dose tigecycline has better effect in the treatment of severe pneumonia caused by pan-resistant Acinetobacter baumannii than conventional dose tigecycline.
作者 王宇飞 冯星火 WANG Yu-fei;FENG Xing-huo(Department of Critical Care Medicine,Liaoning People’s Hospital,Shenyang 110015,China)
出处 《中国现代药物应用》 2021年第1期106-108,共3页 Chinese Journal of Modern Drug Application
关键词 不同剂量 替加环素 泛耐药鲍曼不动杆菌重症肺炎 治疗效果 Different doses Tigecycline Pan-resistant Acinetobacter baumannii Therapeutic effect
  • 相关文献

参考文献14

二级参考文献79

  • 1周颖杰,李光辉.成人及儿童复杂性腹腔内感染的诊断与处理:美国外科感染学会及美国感染病学会指南[J].中国感染与化疗杂志,2010,10(4):241-247. 被引量:241
  • 2王勤鹰,余敏,顾勤,邓冰,姜嘟嘟,赵丽娟,王星,詹青.替加环素治疗重症卒中相关性肺炎3例报道[J].神经病学与神经康复学杂志,2013,10(4):196-198. 被引量:1
  • 3卫生部办公厅.多重耐药菌医院感染预防与控制技术指南(试行).2011-01-17.
  • 4American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare- associated pneumonia[J]. Am J Respir Crit Care Med, 2005, 171(4): 388-416.
  • 5Zavascki A P, Carvalhaes C G, Picoo R C, et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii:resistance mechanisms and implications for therapy[J]. Expert Rev Anti Infect Ther, 2010, 8(1): 71-93.
  • 6Karageorgopoulos D E, Kelesidis T, Kelesidis I, et al. Tigecycline for the treatment of multidrug- resistant(including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence[J]. J Antimicrob Chemother, 2008, 62(1): 45-55.
  • 7Guner R, Hasanoglu I, Keske S, et al. Outcomes in patients infected with carbapenem-resistant Acinetobacter baurnannii and treated with tigecycline alone or in combination therapy[J]. Infection, 201 I, 39(6): 515-518.
  • 8Gallagher J C, Rouse H M. Tigecycline for the treatment of Acinetobaeter infections: a case series[J]. Ann Pharmacother, 2008, 42(9): 1188- 1194.
  • 9Gordon N C, Wareham D W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline[J]. J Antimicrobial Chemother, 2009, 63(4): 775-780.
  • 10Shin J A, Chang Y S, Kim H J, et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection[J]. Yonsei Med J, 2012, 53(5): 974-984.

共引文献169

同被引文献11

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部